IMVT · Insider Trading
Immunovant, Inc. Common Stock
Every open-market purchase and sale reported by IMVT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-09 | Melanie Gloria | Chief Operating Officer | Sell | −2,241 | −$71.85K |
| 2026-10-09 | Christopher Van Tuyl | Chief Legal Officer | Sell | −1,327 | −$42.54K |
| 2026-10-09 | Jay S Stout | Chief Technology Officer | Sell | −3,809 | −$122.12K |
| 2026-10-05 | Eric Venker | Chief Executive Officer | MIXED | +2,795 | −$1.68M |
| 2026-09-25 | Christopher Van Tuyl | Chief Legal Officer | Sell | −2,846 | −$103.48K |
| 2026-08-28 | Atul Pande | Director | MIXED | — | −$52.26K |
| 2026-08-21 | Melanie Gloria | Chief Operating Officer | Sell | −3,056 | −$134.95K |
| 2026-07-24 | Jay S Stout | Chief Technology Officer | Sell | −2,857 | −$110.54K |
| 2026-07-24 | Tiago Girao | Chief Financial Officer | Sell | −6,798 | −$263.01K |
| 2026-07-24 | Atul Pande | Director | MIXED | — | −$47.05K |
| 2026-07-10 | Melanie Gloria | Chief Operating Officer | Sell | −2,036 | −$80.53K |
| 2026-07-10 | Christopher Van Tuyl | Chief Legal Officer | Sell | −1,206 | −$47.70K |
| 2026-07-10 | Jay S Stout | Chief Technology Officer | Sell | −3,487 | −$137.92K |
| 2026-07-06 | Eric Venker | Chief Executive Officer | MIXED | +2,467 | −$2.09M |
| 2026-06-26 | Melanie Gloria | Chief Operating Officer | Sell | −17,714 | −$678.60K |
| 2026-06-26 | Christopher Van Tuyl | Chief Legal Officer | MIXED | — | −$411.96K |
| 2026-06-26 | Atul Pande | Director | MIXED | — | −$44.37K |
| 2026-06-26 | Jay S Stout | Chief Technology Officer | Sell | −40,000 | −$1.53M |
| 2026-06-26 | Tiago Girao | Chief Financial Officer | MIXED | — | −$225.60K |
| 2026-06-22 | Christopher Van Tuyl | Chief Legal Officer | Sell | −2,634 | −$93.22K |
| 2026-06-16 | Atul Pande | Director | MIXED | — | −$38.39K |
| 2026-05-29 | Andrew J. Fromkin | Director | MIXED | −25,350 | −$5.82M |
| 2026-05-22 | Melanie Gloria | Chief Operating Officer | Sell | −3,115 | −$101.07K |
| 2026-05-20 | Atul Pande | Director | MIXED | — | −$141.42K |
| 2026-05-01 | Robert Graham Susman | Director | Sell | −2,502 | −$67.98K |
| 2026-04-24 | Jay S Stout | Chief Technology Officer | Sell | −2,754 | −$81.57K |
| 2026-04-24 | Tiago Girao | Chief Financial Officer | Sell | −25,760 | −$763.01K |
| 2026-04-10 | Melanie Gloria | Chief Operating Officer | Sell | −8,722 | −$216.57K |
| 2026-04-10 | Jay S Stout | Chief Technology Officer | Sell | −10,132 | −$251.58K |
| 2026-04-10 | Christopher Van Tuyl | Chief Legal Officer | Sell | −5,165 | −$128.25K |
| 2026-04-09 | Jake Bauer | Director | A | +13,880 | — |
| 2026-04-09 | Eric Venker | Chief Executive Officer | A | +232,252 | — |
| 2026-04-09 | Andrew J. Fromkin | Director | A | +13,880 | — |
| 2026-04-09 | Robert Graham Susman | Director | A | +13,880 | — |
| 2026-04-09 | Jay S Stout | Chief Technology Officer | A | +66,937 | — |
| 2026-04-09 | Atul Pande | Director | A | +13,880 | — |
| 2026-04-09 | Christopher Van Tuyl | Chief Legal Officer | A | +41,343 | — |
| 2026-04-09 | Douglas J. Hughes | Director | A | +13,880 | — |
| 2026-04-09 | Frank Torti | Director | A | +174,189 | — |
| 2026-04-09 | Tiago Girao | Chief Financial Officer | A | +64,968 | — |
| 2026-04-09 | Melanie Gloria | Chief Operating Officer | A | +83,671 | — |
| 2026-04-03 | Eric Venker | Chief Executive Officer | MIXED | +19,561 | −$3.42M |
| 2026-03-20 | Christopher Van Tuyl | Chief Legal Officer | Sell | −2,877 | −$71.84K |
| 2026-02-27 | Melanie Gloria | Chief Operating Officer | Sell | −3,238 | −$90.18K |
| 2026-01-23 | Jay S Stout | Chief Technology Officer | Sell | −1,977 | −$51.46K |
| 2026-01-09 | Jay S Stout | Chief Technology Officer | Sell | −1,203 | −$31.91K |
| 2025-12-19 | Christopher Van Tuyl | Chief Legal Officer | Sell | −10,813 | −$290.94K |
| 2025-12-12 | Roivant Sciences Ltd. | Director | Buy | +16,666,666 | +$350.00M |
| 2025-12-03 | Andrew J. Fromkin | Director | Sell | −22,249 | −$517.19K |
| 2025-12-03 | Douglas J. Hughes | Director | Sell | −15,000 | −$348.67K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Roivant Sciences Ltd. | Director | 113,317,007 | $3.03B |
| Peter Salzmann | Chief Executive Officer | 1,178,191 | $31.49M |
| Frank Torti | Director | 1,009,228 | $26.98M |
| Eva Renee Barnett | Chief Financial Officer | 396,774 | $10.61M |
| William L. Macias | Chief Medical Officer | 357,353 | $9.55M |
| Mark S. Levine | Chief Legal Officer | 319,228 | $8.53M |
| Eric Venker | Chief Executive Officer | 260,581 | $6.97M |
| Tiago Girao | Chief Financial Officer | 240,798 | $6.44M |
| Michael Geffner | Chief Medical Officer | 217,958 | $5.83M |
| Melanie Gloria | Chief Operating Officer | 217,060 | $5.80M |
| Jay S Stout | Chief Technology Officer | 203,128 | $5.43M |
| Christopher Van Tuyl | Chief Legal Officer | 175,218 | $4.68M |
| Atul Pande | Director | 138,231 | $3.69M |
| George V Migausky | Director | 137,251 | $3.67M |
| Douglas J. Hughes | Director | 134,653 | $3.60M |
| Andrew J. Fromkin | Director | 131,400 | $3.51M |
| Jake Bauer | Director | 38,896 | $1.04M |
| Robert Graham Susman | Director | 36,394 | $972.81K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the IMVT quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.